Transient ischemia reduces norepinephrine release during sustained ischemia. Neural preconditioning in isolated rat heart.
Endogenous catecholamine release may play a role in ischemic preconditioning either as a trigger or as a target within the process of myocardial preconditioning. Therefore, we investigated the effect of transient ischemia (TI) on norepinephrine release during sustained ischemia in isolated rat hearts. TI was induced by multiple cycles of global ischemia followed by reperfusion with a duration of 5 minutes each, comparable to ischemic preconditioning protocols. After TI, norepinephrine release was evoked by either sustained global ischemia, anoxia, cyanide intoxication, tyramine, or electrical stimulation. During TI, no washout of norepinephrine was observed, and tissue concentrations of norepinephrine were not changed. TI, however, reduced norepinephrine overflow after 20 minutes of sustained ischemia from 239 +/- 26 pmol/g (control) to 79+/-8 pmol/g (67% reduction, P <.01 ). A similar reduction of ischemia-induced norepinephrine release from 192 +/- 22 pmol/g (control) to 90 +/- 15 pmol/g was observed when hearts underwent transient anoxia without glucose (P < .05). When reperfusion between TI and sustained ischemia was prolonged from 5 to 90 minutes, the inhibitory effect of TI on norepinephrine release was gradually lost. Susceptibility to TI was a unique feature of norepinephrine release induced by sustained ischemia, since release of norepinephrine evoked by anoxia, cyanide intoxication, tyramine, or electrical stimulation remained unaffected by TI. We propose a protective effect of TI on neural tissue, which may reduce norepinephrine-induced damage during prolonged myocardial ischemia.
Seyfarth
M
M
I. Medizinische Klinik, Technische Universität München, Germany.
Richardt
G
G
Mizsnyak
A
A
Kurz
T
T
Schömig
A
A
D000818:Animals; D003486:Cyanides / Q000506:poisoning; D004558:Electric Stimulation; D006321:Heart / Q000503:physiopathology; D006329:Heart Conduction System / Q000503:physiopathology; D000860:Hypoxia / Q000378:metabolism; D066298:In Vitro Techniques; D002546:Ischemic Attack, Transient / Q000503:physiopathology*; D008297:Male; D017202:Myocardial Ischemia / Q000378:metabolism* / Q000503:physiopathology*; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000502:physiology; D013997:Time Factors; D014439:Tyramine / Q000494:pharmacology
D003486:Cyanides; D011942:Receptors, Adrenergic, alpha; D018047:Receptors, Purinergic P1; D009638:Norepinephrine; D014439:Tyramine